



Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

| | |
|------------------------|-------------------------------|
| Application | 09/699,667 |
| Filing Date | 10/30/00 |
| First Named | Jean-Pierre Perreault, et al. |
| Group Art Unit | 1635 |
| Examiner Name | Jane J. Zara |
| Attorney Docket Number | 285/235 |

RECEIVED
FEB 10 2003
TECH CENTER 1600/2300

| ENCLOSURES (check all that apply) | | |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application) <input checked="" type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <ul style="list-style-type: none"> 1. A Copy Of The Notice To Comply With Requirements. 2. Sequence Listing -Paper Copy 3. Sequence Listing - on Diskette 4. Letter to Draftsperson |
| <input type="checkbox"/> Remarks The Statements of compliance with 37C.F.R. 1.821 (f) and (g) are included. | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | |
|-------------------------|---------------------------------|
| Firm or Individual name | Joy D. Morrow (Reg. No. 30,911) |
| Signature | |
| Date | February 3, 2003 |

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:

| | | |
|-----------------------|--|------|
| Typed or printed name | | Date |
| Signature | | |

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FEB 04 2003

App

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: Please provide appropriate, accompanying Seg ID nos as indicated in Attachment.

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

TECH CENTER 1600/2900
FEB 10 2003

RECEIVED
FEB 10 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Attorney Docket No. 258/235



#16 of
Draws

Re application of Jean-Pierre Perreault, *et al*)
Serial No.: 09/699,667) Art Unit: 1635
Filed: October 30, 2000)
For: NUCLEIC ACID ENZYME FOR RNA CLEAVAGE) Examiner: Jane Z. Zara
)
)
)

LETTER TO THE OFFICIAL DRAFTSPERSON

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

As part of an amendment to this application in response to sequence listing requirements, various figures have been amended to include reference to SEQ ID NOS. Please replace figures 1a, 1b, 2, 3, 4, 6 and 7b of the drawings with the new corresponding figures submitted herewith. Also enclosed are copies of the new figures marked in red to show the changes made.

The amended drawings are consistent with the amended description. No new matter is added.

Respectfully submitted,

Dated: February 3, 2003


(Mrs.) Joy D. Morrow

Reg. No. 30911

Mailing Address:

Jones, Day, Reavis & Pogue
555 West Fifth Street
Suite 4600
Los Angeles, CA 90013-1025
Attorney Docket No. 258/235

RECEIVED
FEB 10 2003
TECH CENTER 1600/2900